ArticleJournal of neuro-oncology2015
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Guideline
- Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.Clinical neuroradiology · 2018Pooled it
- Neuroimaging classification of progression patterns in glioblastoma: a systematic review.Journal of neuro-oncology · 2018Pooled it
- Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.Neuro-oncology · 2024Trial
- Reconstruction matters: influence of EARL standards and BSREM in [EJNMMI research · 2026Article
- Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrence.Brain tumor pathology · 2026Article
- Clinical outcomes of early salvage surgery for residual or enlarging contrast-enhancing lesions after radiotherapy in patients with glioblastoma.Frontiers in oncology · 2026Article
- Site of first treatment failure after standard-of-care for newly diagnosed glioblastoma in a Danish cohort.Neuro-oncology practice · 2025Article
- A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.Neuro-oncology · 2025Review
- A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part II-Essential Information on Post-Treatment Imaging.Korean journal of radiology · 2025Review
- Prospective longitudinal analysis of physiologic MRI-based tumor habitat predicts short-term patient outcomes in IDH-wildtype glioblastoma.Neuro-oncology · 2025Article
- The role of FET-PET in patient selection and response assessment for reirradiation in recurrent glioblastoma.Frontiers in oncology · 2025Review
- Resolving spatial response heterogeneity in glioblastoma.European journal of nuclear medicine and molecular imaging · 2024Article
- Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection.Journal of cancer research and clinical oncology · 2024Article
- Biomarkers of immunotherapy in glioblastoma.Neuro-oncology practice · 2024Review
- Article
- Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.Neuro-oncology practice · 2024Article
- Histopathologically confirmed radiation-induced damage of the brain - an in-depth analysis of radiation parameters and spatio-temporal occurrence.Radiation oncology (London, England) · 2023Article
- Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences.Acta neuropathologica communications · 2023Article
- RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Pseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3 months of chemoRT; of these, 34 underwent surgical resection. Three subsets-tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan-Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32% of cases (11/34) 95%CI 19-49%. A large proportion of patients had a histologically "mixed" pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.